Oncolytics Biotech Overview
Oncolytics Biotech (ONCY) has a ROE of 560.92%, above the Healthcare sector average of 11.15%.
Get informed when a big investor buys or sells
+ Follow560.92%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Oncolytics Biotech (ONCY) currently reports a ROE of 560.92%. That is above the Healthcare sector average of 11.15%. Use the charts on this page to explore Oncolytics Biotech's ROE history and peer comparisons.
Oncolytics Biotech's ROE of 560.92% is higher than the Healthcare sector average of 11.15%. That is roughly 4928.8% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Oncolytics Biotech's current 560.92% should be judged against Healthcare norms (sector average: 11.15%) and against ONCY's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 560.92%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.15%. From there, open related valuation or income-statement pages for Oncolytics Biotech, and consider following ONCY for alerts when major investors trade the stock.
Oncolytics Biotech is classified in the Healthcare sector. On ROE, it currently shows 560.92% versus a sector average near 11.15%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ONCY with unrelated industries.
